Evidence map›Paper›PMID 28416767›Full record

ArticleOncotarget2017

The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients.

Junjie Peng, Dan Huang, Graeme Poston, Xiaoji Ma, Renjie Wang, Weiqi Sheng, Xiaoyan Zhou, Xiaoli Zhu, Sanjun Cai

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. International journal of molecular sciences · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Comparison of microsatellite status detection methods in colorectal carcinoma.International journal of clinical and experimental pathology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Junjie PengDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Dan HuangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Graeme PostonDepartment of Surgery, Aintree University Hospital, Liverpool L9 7AL, UK.
Xiaoji MaDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Renjie WangDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Weiqi ShengDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiaoyan ZhouDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiaoli ZhuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Sanjun CaiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CNAintree University Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the biological variability of clinical meaningful molecular markers and their clinical correlations in Chinese patients with colorectal cancer (CRC). MATERIALS AND

methodsIn this prospective observational study, frequencies and clinico-pathological features of RAS and BRAFV600E mutations, deficiency of DNA mismatch repair (dMMR) were evaluated in patients with colorectal cancer staged I-IV. The molecular heterogeneity between right-sided and left-sided colorectal cancers was studied in our series by classifying patients with different mutations and dMMR status.

resultsAmong 400 evaluable patients, mutations in KRAS exon 2, exon 3 or 4, NRAS and BRAFV600E were detected in 36%, 7.5%, 3.5% and 2.5%, respectively. RAS mutations were significantly higher in metastatic CRCs (56.4% vs. 43.1%, p=0.015) and right-sided CRCs (62.5% vs 41.7%, p=0.003). In 212 RAS wild-type patients, V600E mutation was higher in older patients (9.5% vs. 2.2%, p=0.017), women (9.2% vs. 2.2%, p=0.021) and right-sided CRCs (10.5% vs. 3.4%, p=0.06). dMMR was detected in 7.75% of all stages of CRCs, with the highest dMMR rate of 40% in stage II right-sided colon cancer.

conclusionsBy assessing the mutations and clinical correlations of RAS and BRAF genes, and dMMR status, similar RAS mutation, dMMR frequency and lower BRAF mutation was observed in Chinese patients compared to western patients. A distinct molecular heterogeneity was found between patients with right-sided and left-sided CRCs.

Indexed as

Asian PeopleBiomarkers, TumorAgedAged, 80 and overChinaColorectal NeoplasmsDNA Mismatch RepairExonsFemaleGenetic HeterogeneityHumansMaleMiddle AgedMutationNeoplasm GradingNeoplasm StagingBiomarkers, TumorKRAS protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)BRAFcolorectal cancerheterogeneitymutationRAS

Identifiers

PMID28416767
PMCPMC5564750
OpenAlexW2600742432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.